Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes

Brian D. Green; Peter R. Flatt; Clifford J. Bailey

doi:10.3132/dvdr.2006.024

Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes

Brian D. Green^*, Peter R. Flatt, Clifford J. Bailey

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Inhibitors of the enzyme dipeptidyl peptidase IV (DPP IV) provide a strategy for the treatment of type 2 diabetes. DPP IV rapidly inactivates the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Inhibition of DPPIV prolongs and enhances the activity of endogenous GLP-1 and GIP, which serve as important prandial stimulators of insulin secretion and regulators of blood glucose control. In clinical trials DPP IV inhibitors (or 'gliptins') have shown efficacy and tolerability in the management of hyperglycaemia in type 2 diabetes, without causing weight gain or hypoglycaemia.

Original language	English
Pages (from-to)	159-165
Number of pages	7
Journal	Diabetes and Vascular Disease Research
Volume	3
Issue number	3
DOIs	https://doi.org/10.3132/dvdr.2006.024
Publication status	Published - 1 Dec 2006

Keywords

Dipeptidyl peptidase IV
DPP IV
DPP IV inhibition
Gliptin
Incretin hormones

Access to Document

10.3132/dvdr.2006.024

Cite this

@article{00c702d3a18040f89aea3a6c2d0a3b87,

title = "Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes",

abstract = "Inhibitors of the enzyme dipeptidyl peptidase IV (DPP IV) provide a strategy for the treatment of type 2 diabetes. DPP IV rapidly inactivates the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Inhibition of DPPIV prolongs and enhances the activity of endogenous GLP-1 and GIP, which serve as important prandial stimulators of insulin secretion and regulators of blood glucose control. In clinical trials DPP IV inhibitors (or 'gliptins') have shown efficacy and tolerability in the management of hyperglycaemia in type 2 diabetes, without causing weight gain or hypoglycaemia.",

keywords = "Dipeptidyl peptidase IV, DPP IV, DPP IV inhibition, Gliptin, Incretin hormones",

author = "Green, {Brian D.} and Flatt, {Peter R.} and Bailey, {Clifford J.}",

year = "2006",

month = dec,

day = "1",

doi = "10.3132/dvdr.2006.024",

language = "English",

volume = "3",

pages = "159--165",

journal = "Diabetes and Vascular Disease Research",

issn = "1479-1641",

publisher = "SAGE",

number = "3",

}

TY - JOUR

T1 - Dipeptidyl peptidase IV (DPP IV) inhibitors

T2 - A newly emerging drug class for the treatment of type 2 diabetes

AU - Green, Brian D.

AU - Flatt, Peter R.

AU - Bailey, Clifford J.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Inhibitors of the enzyme dipeptidyl peptidase IV (DPP IV) provide a strategy for the treatment of type 2 diabetes. DPP IV rapidly inactivates the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Inhibition of DPPIV prolongs and enhances the activity of endogenous GLP-1 and GIP, which serve as important prandial stimulators of insulin secretion and regulators of blood glucose control. In clinical trials DPP IV inhibitors (or 'gliptins') have shown efficacy and tolerability in the management of hyperglycaemia in type 2 diabetes, without causing weight gain or hypoglycaemia.

AB - Inhibitors of the enzyme dipeptidyl peptidase IV (DPP IV) provide a strategy for the treatment of type 2 diabetes. DPP IV rapidly inactivates the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Inhibition of DPPIV prolongs and enhances the activity of endogenous GLP-1 and GIP, which serve as important prandial stimulators of insulin secretion and regulators of blood glucose control. In clinical trials DPP IV inhibitors (or 'gliptins') have shown efficacy and tolerability in the management of hyperglycaemia in type 2 diabetes, without causing weight gain or hypoglycaemia.

KW - Dipeptidyl peptidase IV

KW - DPP IV

KW - DPP IV inhibition

KW - Gliptin

KW - Incretin hormones

UR - http://www.scopus.com/inward/record.url?scp=33845468278&partnerID=8YFLogxK

UR - https://journals.sagepub.com/doi/10.3132/dvdr.2006.024

U2 - 10.3132/dvdr.2006.024

DO - 10.3132/dvdr.2006.024

M3 - Article

C2 - 17160910

AN - SCOPUS:33845468278

SN - 1479-1641

VL - 3

SP - 159

EP - 165

JO - Diabetes and Vascular Disease Research

JF - Diabetes and Vascular Disease Research

IS - 3

ER -

Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this